Cargando…

Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates

Spinal Muscular Atrophy (SMA) is a neuromuscular disorder caused by mutations in the SMN1 gene. Being a monogenic disease, it is characterized by high clinical heterogeneity. Variations in penetrance and severity of symptoms, as well as clinical discrepancies between affected family members can resu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maretina, Marianna A., Zheleznyakova, Galina Y., Lanko, Kristina M., Egorova, Anna A., Baranov, Vladislav S., Kiselev, Anton V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030859/ https://www.ncbi.nlm.nih.gov/pubmed/30065610 http://dx.doi.org/10.2174/1389202919666180101154916

Ejemplares similares

Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy
por: Maretina, Marianna, et al.
Publicado: (2022)

Methylation Levels of SLC23A2 and NCOR2 Genes Correlate with Spinal Muscular Atrophy Severity
por: Zheleznyakova, Galina Yu., et al.
Publicado: (2015)

Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III
por: Zheleznyakova, Galina Yu, et al.
Publicado: (2011)

Characterization of iRGD-Ligand Modified Arginine-Histidine-Rich Peptides for Nucleic Acid Therapeutics Delivery to αvβ3 Integrin-Expressing Cancer Cells
por: Egorova, Anna, et al.
Publicado: (2020)

Peptide Nanoparticle-Mediated Combinatorial Delivery of Cancer-Related siRNAs for Synergistic Anti-Proliferative Activity in Triple Negative Breast Cancer Cells
por: Egorova, Anna, et al.
Publicado: (2021)

Magnetic Nanoparticles as a Component of Peptide-Based DNA Delivery System for Suicide Gene Therapy of Uterine Leiomyoma
por: Shtykalova, Sofia, et al.
Publicado: (2022)

Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma
por: Egorova, Anna, et al.
Publicado: (2021)

Polycondensed Peptide Carriers Modified with Cyclic RGD Ligand for Targeted Suicide Gene Delivery to Uterine Fibroid Cells
por: Egorova, Anna, et al.
Publicado: (2022)

iRGD-Targeted Peptide Nanoparticles for Anti-Angiogenic RNAi-Based Therapy of Endometriosis
por: Egorova, Anna, et al.
Publicado: (2023)

Synergistic Anti-Angiogenic Effects Using Peptide-Based Combinatorial Delivery of siRNAs Targeting VEGFA, VEGFR1, and Endoglin Genes
por: Egorova, Anna A., et al.
Publicado: (2019)

Cardiac involvement in patients with Spinal Muscular Atrophies
por: Palladino, Alberto, et al.
Publicado: (2011)

Peptide-Based Nanoparticles for αvβ3 Integrin-Targeted DNA Delivery to Cancer and Uterine Leiomyoma Cells
por: Egorova, Anna, et al.
Publicado: (2022)

Development of 2′-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells
por: Maretina, Marianna, et al.
Publicado: (2023)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Investigation on the Effects of Modifying Genes on the Spinal Muscular Atrophy Phenotype
por: Zhuri, Drenushe, et al.
Publicado: (2022)

Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy
por: Baranello, Giovanni, et al.
Publicado: (2021)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Neuronal involvement in muscular atrophy
por: Cisterna, Bruno A., et al.
Publicado: (2014)

Modeling Spinal Muscular Atrophy in Drosophila
por: Chang, Howard Chia-Hao, et al.
Publicado: (2008)

Carrier screening for spinal muscular atrophy
por: Prior, Thomas W.
Publicado: (2008)

Androgens in spinal and bulbar muscular atrophy
Publicado: (2012)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Euglycemic Ketoacidosis in Spinal Muscular Atrophy
por: Stoimenis, Dimitrios, et al.
Publicado: (2019)

Metabolic Dysfunction in Spinal Muscular Atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Editorial: Advances in spinal muscular atrophy
por: Sun, Jianli
Publicado: (2023)

Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification
por: Proud, Crystal M., et al.
Publicado: (2023)

Candidate Proteins, Metabolites and Transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study
por: Finkel, Richard S., et al.
Publicado: (2012)

Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy
por: Lusakowska, Anna, et al.
Publicado: (2021)

Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy
por: Walsh, Melissa B., et al.
Publicado: (2020)

Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment
por: Pierzchlewicz, Katarzyna, et al.
Publicado: (2021)

Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey
por: Coratti, Giorgia, et al.
Publicado: (2023)

Mitochondrial abnormalities in spinal and bulbar muscular atrophy
por: Ranganathan, Srikanth, et al.
Publicado: (2009)

Rapid molecular diagnosis of spinal muscular atrophy
por: Mittal, Balraj
Publicado: (2012)

Clinical features of spinal and bulbar muscular atrophy
por: Rhodes, Lindsay E., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_rvbvk7ek01k4ghv4eeio0orm8v